No Effect of the 1α,25-Dihydroxyvitamin D3 on β-Cell Residual Function and Insulin Requirement in Adults With New-Onset Type 1 Diabetes

OBJECTIVE To determine whether daily intake of 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3] is safe and improves β-cell function in patients with recently diagnosed type 1 diabetes. RESEARCH DESIGN AND METHODS Safety was assessed in an open study of 25 patients aged 18–39 years with recent-onset type 1 diabetes who received 0.25 μg 1,25(OH)2D3 daily for 9 months. An additional 40 patients were randomly assigned to 0.25 μg 1,25(OH)2D3 or placebo daily for 9 months and followed for a total of 18 months for safety, β-cell function, insulin requirement, and glycemic control. RESULTS Safety assessment showed values in the normal range in nearly all patients, regardless of whether they received 1,25(OH)2D3 or placebo. No differences in AUC C-peptide, peak C-peptide, and fasting C-peptide after a mixed-meal tolerance test between the treatment and placebo groups were observed at 9 and 18 months after study entry, with ∼40% loss for each parameter over the 18-month period. A1C and daily insulin requirement were similar between treatment and placebo groups throughout the study follow-up period. CONCLUSIONS Treatment with 1,25(OH)2D3 at a daily dose of 0.25 μg was safe but did not reduce loss of β-cell function.

[1]  C. Drevon,et al.  Serum Vitamin D Concentration Does Not Predict Insulin Action or Secretion in European Subjects With the Metabolic Syndrome , 2010, Diabetes Care.

[2]  A. Ziegler,et al.  No Effect of the Altered Peptide Ligand NBI-6024 on β-Cell Residual Function and Insulin Needs in New-Onset Type 1 Diabetes , 2009, Diabetes Care.

[3]  M. Atkinson,et al.  Vitamin D Levels in Subjects With and Without Type 1 Diabetes Residing in a Solar Rich Environment , 2009, Diabetes Care.

[4]  E. Bonifacio,et al.  Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk , 2009, Diabetologia.

[5]  Xiang Yan,et al.  Protective effects of 1‐α‐hydroxyvitamin D3 on residual β‐cell function in patients with adult‐onset latent autoimmune diabetes (LADA) , 2009, Diabetes/metabolism research and reviews.

[6]  D. Teegarden,et al.  Vitamin D: emerging new roles in insulin sensitivity , 2009, Nutrition Research Reviews.

[7]  J. Kouba,et al.  Vitamin D and Diabetes , 2008, The Diabetes educator.

[8]  A. Akobeng,et al.  Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis , 2008, Archives of Disease in Childhood.

[9]  M. Peakman,et al.  Translational Mini‐Review Series on Type 1 Diabetes: Immune‐based therapeutic approaches for type 1 diabetes , 2007, Clinical and experimental immunology.

[10]  L. Adorini,et al.  1,25-Dihydroxyvitamin D3 Selectively Modulates Tolerogenic Properties in Myeloid but Not Plasmacytoid Dendritic Cells1 , 2007, The Journal of Immunology.

[11]  P. Pozzilli,et al.  The effects of calcitriol and nicotinamide on residual pancreatic β‐cell function in patients with recent‐onset Type 1 diabetes (IMDIAB XI) , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[12]  C. Mathieu,et al.  1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. , 2005, Endocrinology.

[13]  L. C. Stene,et al.  Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. , 2003, The American journal of clinical nutrition.

[14]  C. Mathieu,et al.  Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). , 2002, Diabetes.

[15]  M. Uskoković,et al.  A 1α,25-Dihydroxyvitamin D3 Analog Enhances Regulatory T-Cells and Arrests Autoimmune Diabetes in NOD Mice , 2002 .

[16]  C. Mathieu,et al.  Treatment of autoimmune diabetes recurrence in non‐obese diabetic mice by mouse interferon‐β in combination with an analogue of 1α,25‐dihydroxyvitamin‐D3 , 2002 .

[17]  C. Mathieu,et al.  Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-beta in combination with an analogue of 1alpha,25-dihydroxyvitamin-D3. , 2002, Clinical and experimental immunology.

[18]  M. Uskoković,et al.  A 1 , 25-Dihydroxyvitamin D 3 Analog Enhances Regulatory T-Cells and Arrests Autoimmune Diabetes in NOD Mice , 2002 .

[19]  Elina Hyppönen,et al.  Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study , 2001, The Lancet.

[20]  Huub F. J. Savelkoul,et al.  1α,25-Dihydroxyvitamin D3 Has a Direct Effect on Naive CD4+ T Cells to Enhance the Development of Th2 Cells1 , 2001, The Journal of Immunology.

[21]  M. Atkinson,et al.  Type 1 diabetes: new perspectives on disease pathogenesis and treatment , 2001, The Lancet.

[22]  R. Kumar,et al.  Dendritic cell modulation by 1α,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Boonstra,et al.  25-Dihydroxyvitamin D 3 Has a Direct Effect on Naive CD 4 T Cells to Enhance the Development of Th 2 Cells 1 , 2001 .

[24]  P. Allavena,et al.  Vitamin D3 Affects Differentiation, Maturation, and Function of Human Monocyte-Derived Dendritic Cells1 , 2000, The Journal of Immunology.

[25]  L. Adorini,et al.  1α,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation , 2000, The Journal of Immunology.

[26]  T. S. Group.  Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus , 1999 .

[27]  C. Beaufort.  The EURODIAB Substudy 2 Study Group Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus , 1999 .

[28]  M. Cippitelli,et al.  Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. , 1998, The Journal of clinical investigation.

[29]  A. Ziegler,et al.  Changes of vitamin D3 serum concentrations at the onset of immune-mediated type 1 (insulin-dependent) diabetes mellitus. , 1991, Diabetes research.